Leap Therapeutics (LPTX) to Release Earnings on Monday

Leap Therapeutics (NASDAQ:LPTX) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.

Leap Therapeutics Stock Performance

Shares of NASDAQ:LPTX opened at $0.40 on Friday. Leap Therapeutics has a 52-week low of $0.39 and a 52-week high of $4.79. The firm has a market capitalization of $15.33 million, a PE ratio of -0.21 and a beta of 0.35. The firm has a fifty day moving average of $1.23 and a 200 day moving average of $2.34.

Analysts Set New Price Targets

LPTX has been the subject of several recent analyst reports. HC Wainwright lowered shares of Leap Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 29th. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th. Finally, Robert W. Baird lowered shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.